NCT01114880 - Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis | Biotech Hunter

Enrollment

344

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

February 28, 2011

Conditions

Ankylosing Spondylitis

Interventions

BIOLOGICAL

adalimumab

Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week

OTHER

placebo

Prefilled syringe, matching placebo administered subcutaneously every other week

Trial Locations (9)

Site Reference ID/Investigator# 25522, Beijing

Site Reference ID/Investigator# 24055, Beijing

Site Reference ID/Investigator# 24052, Beijing

Site Reference ID/Investigator# 24053, Shanghai

Site Reference ID/Investigator# 24058, Shanghai

Site Reference ID/Investigator# 24054, Hefei

Site Reference ID/Investigator# 24243, Hangzhou

Site Reference ID/Investigator# 24056, Guangzhou

Site Reference ID/Investigator# 24057, Xi'an